KRT28: A Potential Drug Target and Biomarker (G162605)

Target Name: KRT28

NCBI ID: G162605

KRT28

KRT28: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KRTs) are a family of serine proteases that belong to the subfamily of proteases that regulate matrix metalloproteinases (MMPs). These enzymes are involved in the regulation of extracellular matrix (ECM) components, including ECM degradation, cell-cell adhesion, and tissue repair. KRTs have been identified as potential drug targets due to their involvement in various physiological processes and their ability to modulate ECM composition and mechanical properties of tissues. In this article, we will discuss the potential drug target and biomarker KRT28, its structure, function, and potential therapeutic applications.

Structure and Function

KRT28 is a 28-kDa protein that belongs to the Kallikrein-related peptidases family 28 (KRT28 family). This protein is derived from the extracellular matrix (ECM) component called type II collagen. KRT28 is localized to the cytoskeleton and is involved in the regulation of ECM degradation and cell-cell adhesion.

KRT28 functions as a potent protease that can cleave various ECM components, including collagen, laminin, and hyaluronic acid. This protease activity is critical for the regulation of ECM homeostasis and is involved in various physiological processes, including tissue repair, embryonic development, and cancer progression.

KRT28 has been shown to play a role in the regulation of cell-cell adhesion and migration. It has been shown to promote the formation of tight junctions between epithelial cells and to regulate the migration of cancer cells. Additionally, KRT28 has been shown to contribute to the regulation of stem cell self-renewal and has been identified as a potential therapeutic target for cancer stem cell therapies.

Potential Therapeutic Applications

KRT28 has been identified as a potential drug target due to its involvement in various physiological processes. The therapeutic use of KRT28 may involve the inhibition of its protease activity to treat diseases characterized by hyperactive ECM degradation and cell-cell adhesion.

KRT28 has been shown to be involved in the regulation of fetal development and has been identified as a potential therapeutic target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that inhibition of KRT28 can lead to the regression of cancer tumors and improve the survival of neurodegenerative diseases.

In addition to its potential therapeutic applications, KRT28 has also been shown to have potential as a biomarker for various diseases. The KRT28 gene has been shown to be expressed in a variety of tissues and has been used as a biomarker for diseases characterized by hyperactive ECM degradation, including cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

Kallikrein-related peptidases (KRTs) have been identified as potential drug targets due to their involvement in various physiological processes and their ability to modulate ECM composition and mechanical properties of tissues. KRT28 is a 28-kDa protein that belongs to the KRT28 family and functions as a potent protease that can cleave various ECM components. The therapeutic use of KRT28 may involve the inhibition of its protease activity to treat diseases characterized by hyperactive ECM degradation and cell-cell adhesion. Additionally, KRT28 has also been shown to have potential as a biomarker for various diseases. Further research is needed to fully understand the role of KRT28 in various physiological processes and to develop effective therapies based on this protein.

Protein Name: Keratin 28

Functions: Essential for the proper assembly of types I and II keratin protein complexes and the formation of keratin intermediate filaments in the inner root sheath (irs)

The "KRT28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets